Viridian Therapeutics, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Viridian Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of novel therapies primarily targeting serious and rare autoimmune diseases. The company’s core product portfolio includes veligrotug (VRDN-001), an intravenous humanized monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R) for the treatment of thyroid eye disease (TED), and VRDN-003, a subcutaneous formulation of the same antibody. Additionally, Viridian is developing a pipeline of neonatal Fc receptor (FcRn) inhibitors including VRDN-006 and VRDN-008 for potential treatment of autoimmune conditions. These products leverage the company's expertise in antibody discovery and protein engineering. Founded in 2011 and headquartered in Waltham, Massachusetts, Viridian Therapeutics operates globally with strategic collaborations that extend its commercial reach. A major recent development includes a licensing and collaboration agreement with Kissei Pharmaceutical to develop and commercialize veligrotug and VRDN-003 in Japan, accompanied by a $70 million upfront payment and potential milestones exceeding $315 million, plus royalties. In October 2025, Viridian successfully submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration for veligrotug, targeting a potential U.S. commercial launch by mid-2026 under Priority Review. The company also closed a comprehensive financing package in October 2025, including royalty financing from DRI Healthcare Acquisitions of up to $300 million, to support commercialization and continued clinical development. The company’s late-stage clinical programs demonstrated positive Phase 3 results: veligrotug showed significant efficacy in reducing proptosis and diplopia in TED patients in global THRIVE and THRIVE-2 studies, with strong durability of response at 52 weeks, while VRDN-003’s pivotal trials REVEAL-1 and REVEAL-2 are ongoing to confirm efficacy and safety for subcutaneous administration. Viridian’s strategic focus is on establishing a leading position in the treatment of thyroid eye disease while advancing its FcRn inhibitor candidates for broader autoimmune disease indications. The company also recently secured an extensive financial foundation aimed at reaching profitability and supporting future growth initiatives in the biopharmaceutical sector.
VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know
Viridian Therapeutics: Lumvoa Ready For Prime Time Following FDA Approval
Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcript
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
Viridian Therapeutics: A Two-Step TED Franchise With More Leverage Than The Market Appreciates
Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Viridian Metals Commences 2026 Diamond Drill Program at the Kraken
Viridian Metals Highlights Copper-Rich Zones up to 4.15% Cu at Kraken Ahead of 2026 Drill Program
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
Viridian Metals Expands Drill Program to 50 Holes at Kraken Copper-Nickel Project
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million
Viridian Metals Announces Flow-Through Private Placement, Warrant Extension and Date of Annual General and Special Meeting
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease Transcript
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
Alpha Tau Reports 100% Local Disease Control in Early Pancreatic Cancer Data as Program Gains Momentum (DRTS)
Viridian Shares Climb As Trial Data Reinforces Position In Thyroid Eye Disease Market
Viridian eye disease drug benefits chronic patients in late-stage trial